drugset / Trial / NCT04098250
Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH
Phase 2
Completed
6 enrolled
Mayo Clinic
Amgen · collabArizona State University · collabGeorgia Institute of Technology · collabPhoenix VA Health Care System · collabTranslational Genomics Research Institute · collabUnited States Department of Defense · collabUniversity of Arizona · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
This is a United States Department of Defense funded Focused Program study that aims to identify mechanisms and predictors for persistent of post-traumatic headache attributed to mild traumatic brain injury, and identify methods of preventing post-traumatic headache persistence. The objective of the clinical trial component of the Focused Program is to determine whether intervention with erenumab is an effective treatment for PTH attributed to mTBI.
Timeline
- Start
- 2021-01-04
- Primary completion
- 2024-01-10
- Completion
- 2024-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erenumab | Monoclonal antibody | 140 mg | — |
Indications
No indication recorded.